Darlene Floden1, Robyn M Busch2, Scott E Cooper3, Cynthia S Kubu1, Andre G Machado1. 1. Center for Neurological Restoration, Cleveland Clinic, Cleveland, Ohio, USA. 2. Epilepsy Center, Cleveland Clinic, Cleveland, Ohio, USA. 3. Department of Neurology, University of Minnesota, Minneapolis, Minnesota, USA.
Abstract
BACKGROUND: Presence of dementia is a contraindication for DBS treatment of Parkinson's disease. Recent evidence suggests that borderline cognitive function, as measured with a common screening measure, the Mattis Dementia Rating Scale, has a negative impact on quality of life (QoL) after DBS of the STN. METHODS: We attempted to replicate and extend this finding in a larger group of patients with a wider range of preoperative global cognitive performance. RESULTS: Our data indicate that performance on the screening measure is not associated with QoL or medical outcomes, even with scores well below the cutoff for identifying dementia. CONCLUSIONS: This cognitive screening measure lacks sufficient sensitivity to warrant its use in predicting which patients will show QoL benefit from DBS.
BACKGROUND: Presence of dementia is a contraindication for DBS treatment of Parkinson's disease. Recent evidence suggests that borderline cognitive function, as measured with a common screening measure, the Mattis Dementia Rating Scale, has a negative impact on quality of life (QoL) after DBS of the STN. METHODS: We attempted to replicate and extend this finding in a larger group of patients with a wider range of preoperative global cognitive performance. RESULTS: Our data indicate that performance on the screening measure is not associated with QoL or medical outcomes, even with scores well below the cutoff for identifying dementia. CONCLUSIONS: This cognitive screening measure lacks sufficient sensitivity to warrant its use in predicting which patients will show QoL benefit from DBS.
Authors: Irene Litvan; Jennifer G Goldman; Alexander I Tröster; Ben A Schmand; Daniel Weintraub; Ronald C Petersen; Brit Mollenhauer; Charles H Adler; Karen Marder; Caroline H Williams-Gray; Dag Aarsland; Jaime Kulisevsky; Maria C Rodriguez-Oroz; David J Burn; Roger A Barker; Murat Emre Journal: Mov Disord Date: 2012-01-24 Impact factor: 10.338
Authors: G G Brown; A A Rahill; J M Gorell; C McDonald; S J Brown; M Sillanpaa; C Shults Journal: J Geriatr Psychiatry Neurol Date: 1999 Impact factor: 2.680
Authors: J Green; W M McDonald; J L Vitek; M Evatt; A Freeman; M Haber; R A E Bakay; S Triche; B Sirockman; M R DeLong Journal: Neurology Date: 2002-11-12 Impact factor: 9.910
Authors: Christine Daniels; Paul Krack; Jens Volkmann; Jan Raethjen; Markus O Pinsker; Manja Kloss; Volker Tronnier; Alfons Schnitzler; Lars Wojtecki; Kai Bötzel; Adrian Danek; Rüdiger Hilker; Volker Sturm; Andreas Kupsch; Elfriede Karner; Günther Deuschl; Karsten Witt Journal: Mov Disord Date: 2011-08-25 Impact factor: 10.338
Authors: Panagiotis Bargiotas; Lukas Eugster; Michael Oberholzer; Ines Debove; M Lenard Lachenmayer; Johannes Mathis; Claudio Pollo; W M Michael Schüpbach; Claudio L Bassetti Journal: PLoS One Date: 2017-12-18 Impact factor: 3.240
Authors: Fernando Alonso-Frech; Carla Fernandez-Garcia; Victor Gómez-Mayordomo; Mariana H G Monje; Celia Delgado-Suarez; Clara Villanueva-Iza; Maria Jose Catalan-Alonso Journal: Front Neurol Date: 2022-01-31 Impact factor: 4.003